Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report) and Cardiol Therapeutics (NASDAQ:CRDL – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.
Risk & Volatility
Black Diamond Therapeutics has a beta of 2.49, meaning that its stock price is 149% more volatile than the S&P 500. Comparatively, Cardiol Therapeutics has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500.
Valuation and Earnings
This table compares Black Diamond Therapeutics and Cardiol Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Black Diamond Therapeutics | N/A | N/A | -$82.44 million | ($1.33) | -1.69 |
| Cardiol Therapeutics | $60,000.00 | 1,702.15 | -$20.84 million | ($0.39) | -3.21 |
Institutional and Insider Ownership
95.5% of Black Diamond Therapeutics shares are held by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are held by institutional investors. 8.9% of Black Diamond Therapeutics shares are held by company insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Analyst Recommendations
This is a summary of current ratings for Black Diamond Therapeutics and Cardiol Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Black Diamond Therapeutics | 0 | 0 | 4 | 0 | 3.00 |
| Cardiol Therapeutics | 0 | 0 | 4 | 1 | 3.20 |
Black Diamond Therapeutics presently has a consensus price target of $15.50, indicating a potential upside of 588.89%. Cardiol Therapeutics has a consensus price target of $8.75, indicating a potential upside of 600.00%. Given Cardiol Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Cardiol Therapeutics is more favorable than Black Diamond Therapeutics.
Profitability
This table compares Black Diamond Therapeutics and Cardiol Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Black Diamond Therapeutics | N/A | -68.08% | -49.65% |
| Cardiol Therapeutics | N/A | -194.40% | -129.07% |
About Black Diamond Therapeutics
Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
About Cardiol Therapeutics
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
Receive News & Ratings for Black Diamond Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Diamond Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
